Scalper1 News
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy’s Cosmo Pharmaceuticals’ Irish subsidiary, Cosmo Technologies. The new headquarters will be in Ireland, which boasts lower taxes than the U.S. Both drug companies focus on finding treatments for gastrointestinal diseases. Inversions have been Scalper1 News
Scalper1 News